Concord Drugs

33.00
+1.10
(3.45%)
Market Cap
33.00 Cr
EPS
0.47
PE Ratio
74.26
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
44.96
52 Week low
26.10
PB Ratio
0.94
Debt to Equity
0.53
Add Ratio

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,573.10 3,77,439.38 32.18 49,887.20 12.06 9,648 13.77 30.18
5,602.00 1,48,715.50 70.82 8,184.00 0.89 1,600 64.53 38.21
1,432.05 1,15,654.37 22.96 26,520.70 14.17 4,155 47.38 42.29
2,990.85 1,01,223.95 54.19 10,785.70 11.59 1,656 13.54 39.65
2,290.30 94,490.20 46.25 10,615.60 19.57 1,942 -16.38 36.88
1,120.30 93,479.05 17.50 28,905.40 12.36 5,578 1.69 30.69
914.15 91,984.88 19.70 19,831.50 13.82 3,831 29.92 40.42
2,007.70 91,590.78 31.98 20,141.50 19.94 1,936 38.82 48.46
31,391.35 66,704.43 49.98 6,097.20 10.80 1,201 16.01 68.32
1,107.60 64,329.59 18.00 29,559.20 17.55 3,169 -10.04 42.06
Growth Rate
Revenue Growth
-13.82 %
Net Income Growth
-50.00 %
Cash Flow Change
-52.41 %
ROE
-54.98 %
ROCE
-17.47 %
EBITDA Margin (Avg.)
2.62 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
16
13
14
14
12
9
8
13
16
12
12
11
Expenses
15
12
13
12
11
8
6
12
15
11
12
9
EBITDA
1
1
1
1
1
2
2
1
0
1
1
1
Operating Profit %
4 %
8 %
9 %
11 %
8 %
16 %
21 %
5 %
2 %
7 %
7 %
13 %
Depreciation
0
0
1
0
0
0
0
0
0
0
0
0
Interest
0
0
0
0
1
0
0
1
1
0
1
1
Profit Before Tax
0
0
0
1
0
1
1
-0
-1
0
0
1
Tax
0
0
0
0
0
0
0
0
-0
0
0
0
Net Profit
0
0
0
0
0
1
1
-0
-0
0
0
0
EPS in ₹
0.03
0.21
0.21
0.52
0.17
0.53
0.60
-0.24
-0.34
0.03
0.04
0.23

Balance Sheet

Balance Sheet
2022
2023
2024
Total Assets
56
58
59
Fixed Assets
14
13
12
Current Assets
42
44
45
Capital Work in Progress
1
1
2
Investments
0
1
1
Other Assets
42
44
45
Total Liabilities
56
58
59
Current Liabilities
24
22
21
Non Current Liabilities
4
5
4
Total Equity
28
32
34
Reserve & Surplus
20
22
24
Share Capital
9
9
10

Cash Flow

Cash Flow
2022
2023
2024
Net Cash Flow
0
0
0
Investing Activities
-2
-2
-1
Operating Activities
1
2
1
Financing Activities
2
1
0

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Oct 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
44.38 %
49.00 %
49.00 %
49.00 %
49.00 %
49.00 %
49.00 %
49.00 %
52.13 %
52.13 %
52.13 %
55.41 %
55.41 %
55.41 %
55.41 %
54.39 %
54.39 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
54.90 %
50.05 %
50.05 %
50.47 %
50.65 %
50.68 %
50.67 %
50.71 %
47.60 %
47.59 %
47.54 %
44.29 %
44.27 %
44.28 %
44.30 %
45.11 %
45.11 %
Others
0.73 %
0.95 %
0.95 %
0.53 %
0.35 %
0.32 %
0.33 %
0.29 %
0.27 %
0.28 %
0.33 %
0.30 %
0.32 %
0.31 %
0.29 %
0.50 %
0.50 %
No of Share Holders
2,173
2,826
2,826
3,071
3,047
3,036
3,188
3,321
3,215
3,198
3,957
3,963
4,032
4,734
4,755
5,073
5,073

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Corporate Action

Announcements

Board Meeting Intimation for To Consider Fund Raising By Way Of Preferential Issue
1 day ago
Integrated Filing (Financial)
Jan 27, 2025, 13:50
Announcement under Regulation 30 (LODR)-Newspaper Publication
Jan 17, 2025, 13:50
Board Meeting Outcome for Outcome Of Board Meeting
Jan 11, 2025, 16:47
Financial Results For 31St December2024
Jan 11, 2025, 16:44
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Jan 07, 2025, 16:33
Board Meeting Intimation for Consider And Approval Of Un-Audited Financial Results
Jan 07, 2025, 16:29
Announcement under Regulation 30 (LODR)-Newspaper Publication
Nov 15, 2024, 13:03
Financial Results For Q2 Ending Sep 30, 2024
Nov 13, 2024, 20:03
Board Meeting Outcome for Financial Results For Quarter Ended 30 September 2024
Nov 13, 2024, 19:59
Board Meeting Intimation for Quarterly Results For 30 September, 2024
Nov 06, 2024, 16:34
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Oct 21, 2024, 15:56
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Oct 01, 2024, 22:24
Closure of Trading Window
Sep 30, 2024, 20:58
Shareholder Meeting / Postal Ballot-Outcome of AGM
Sep 30, 2024, 20:54
Revised Outcome Of Board Meeting.
Sep 30, 2024, 20:51
Financial Results For Q1 JUNE 2024
Sep 12, 2024, 18:55
Announcement under Regulation 30 (LODR)-Newspaper Publication
Sep 10, 2024, 18:07
Reg. 34 (1) Annual Report.
Sep 06, 2024, 18:48
Book Closure.
Sep 06, 2024, 18:32
Annual General Meeting To Be Held On 30.09.2024
Sep 06, 2024, 18:28
Board Meeting Outcome for Outcome Of Board Meeting
Sep 06, 2024, 18:23
Board Meeting Intimation for Meeting To Be Held On 06.09.2024.
Sep 02, 2024, 16:27
Announcement under Regulation 30 (LODR)-Newspaper Publication
Aug 11, 2024, 14:15
Re-Submission Of Financial Results For Year/Quarter Ended 31.03.2024
Aug 09, 2024, 19:14
Board Meeting Outcome for Outcome Of Board Meeting
Aug 09, 2024, 18:58
Declaration Of Financial Results For Quarter Ended 30.06.2024
Aug 09, 2024, 18:54
Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited(Standalone & Consolidated) Financial Results For 1St Quarter, 2024 .
Aug 03, 2024, 14:38
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Jul 16, 2024, 14:54
Closure of Trading Window
Jun 30, 2024, 11:12
Announcement under Regulation 30 (LODR)-Newspaper Publication
Jun 01, 2024, 13:39
Compliances-Reg.24(A)-Annual Secretarial Compliance
May 30, 2024, 22:31
Results For Financial Year Ending March 31St 2024
May 30, 2024, 19:36
Board Meeting Outcome for Audited Results For Financial Year 2023-2024
May 30, 2024, 19:29
Update on board meeting
May 24, 2024, 18:01
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
May 21, 2024, 18:10
Board Meeting Intimation for Audited Financial Results (Standalone & Consolidated) For The Quarter Ended 31.03.2024.
May 15, 2024, 16:42
Compliance Under Regulation 40(9) Of SEBI (LODR)
Apr 30, 2024, 21:32
For Year Ended 31.03.2024
Apr 30, 2024, 17:58
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Apr 15, 2024, 19:05
Certificate Under Regulation 74(5) Of SEBI (Depositories And Participants) Regulations, 2018 .
Apr 15, 2024, 18:57
Closure of Trading Window
Mar 29, 2024, 14:55
Appointment of Company Secretary and Compliance Officer
Mar 19, 2024, 15:36
Board Meeting Outcome for Appointment Of Company Secretary Cum Compliance Officer
Mar 19, 2024, 15:32
Un-Audited Financial Results (Standalone And Consolidated) For The Quarter Ended 31St December, 2023.
Feb 13, 2024, 18:17
Board Meeting Outcome for Un-Audited Financial Results (Standalone And Consolidated) For The Quarter Ended 31* December, 2023.
Feb 13, 2024, 18:15
Board Meeting Intimation for Un-Audited Financial Results (Standalone And Consolidated) For The Quarter Ended 31.12.2023.
Feb 06, 2024, 13:42
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Jan 20, 2024, 13:25
Clarification
Jan 04, 2024, 17:33
Clarification sought from Concord Drugs Ltd
Dec 29, 2023, 19:08

Technical Indicators

RSI(14)
Neutral
46.61
ATR(14)
Less Volatile
3.42
STOCH(9,6)
Neutral
33.88
STOCH RSI(14)
Neutral
43.05
MACD(12,26)
Bearish
-0.20
ADX(14)
Strong Trend
27.71
UO(9)
Bearish
40.30
ROC(12)
Downtrend And Accelerating
-2.51
WillR(14)
Neutral
-47.98